These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 6732862)
41. Inhibition of purified lysosomal phospholipase A1 by beta-adrenoceptor blockers. Pappu AS; Yazaki PJ; Hostetler KY Biochem Pharmacol; 1985 Feb; 34(4):521-4. PubMed ID: 2857566 [TBL] [Abstract][Full Text] [Related]
42. Effects of phospholipase A2 on the lysosomal ion permeability and osmotic sensitivity. Wang JW; Sun L; Hu JS; Li YB; Zhang GJ Chem Phys Lipids; 2006; 144(2):117-26. PubMed ID: 16982042 [TBL] [Abstract][Full Text] [Related]
43. Translocation of phospholipase A2 from cytosol to membranes in rat brain induced by calcium ions. Yoshihara Y; Watanabe Y Biochem Biophys Res Commun; 1990 Jul; 170(2):484-90. PubMed ID: 2383255 [TBL] [Abstract][Full Text] [Related]
44. Purification and characterization of a calcium-independent acidic phospholipase A2 from rat lung. Wang R; Dodia CR; Jain MK; Fisher AB Biochem J; 1994 Nov; 304 ( Pt 1)(Pt 1):131-7. PubMed ID: 7998924 [TBL] [Abstract][Full Text] [Related]
45. Effects of antimalarial drugs on phospholipase A and lysophospholipase activities in plasma membrane, mitochondrial, microsomal and cytosolic subcellular fractions of rat liver. Löffler BM; Bohn E; Hesse B; Kunze H Biochim Biophys Acta; 1985 Jul; 835(3):448-55. PubMed ID: 4016141 [TBL] [Abstract][Full Text] [Related]
46. Variabilin: a dual inhibitor of human secretory and cytosolic phospholipase A2 with anti-inflammatory activity. Escrig V; Ubeda A; Ferrandiz ML; Darias J; Sanchez JM; Alcaraz MJ; Paya M J Pharmacol Exp Ther; 1997 Jul; 282(1):123-31. PubMed ID: 9223548 [TBL] [Abstract][Full Text] [Related]
47. New mechanisms for effects of anti-inflammatory glucocorticoids. Bailey JM Biofactors; 1991 Jun; 3(2):97-102. PubMed ID: 1832865 [TBL] [Abstract][Full Text] [Related]
48. Characterization and partial purification of 'renocortins': two polypeptides formed in renal cells causing the anti-phospholipase-like action of glucocorticoids. Cloix JF; Colard O; Rothhut B; Russo-Marie F Br J Pharmacol; 1983 May; 79(1):313-21. PubMed ID: 6575852 [TBL] [Abstract][Full Text] [Related]
50. Evidence for a direct inhibitory effect of glucocorticoids on the activity of phospholipase A2 as a further possible mechanism of some actions of steroidal anti-inflammatory drugs. Mentz P; Giessler C; Förster W Pharmacol Res Commun; 1980 Sep; 12(8):817-27. PubMed ID: 7443764 [No Abstract] [Full Text] [Related]
51. Localization of phospholipase A2 in normal and ras-transformed cells. Bar-Sagi D; Suhan JP; McCormick F; Feramisco JR J Cell Biol; 1988 May; 106(5):1649-58. PubMed ID: 3286660 [TBL] [Abstract][Full Text] [Related]
52. Further characterization of the glucocorticoid-induced antiphospholipase protein "renocortin". Rothhut B; Russo-Marie F; Wood J; DiRosa M; Flower RJ Biochem Biophys Res Commun; 1983 Dec; 117(3):878-84. PubMed ID: 6667275 [TBL] [Abstract][Full Text] [Related]
53. Selective release of phospholipase A2 and lysophosphatidylserine-specific lysophospholipase from rat platelets. Horigome K; Hayakawa M; Inoue K; Nojima S J Biochem; 1987 Jan; 101(1):53-61. PubMed ID: 3571210 [TBL] [Abstract][Full Text] [Related]
54. Lipocortin and vasocortin: two species of anti-inflammatory proteins mimicking the effects of glucocorticoids. Sautebin L; Carnuccio R; Ialenti A; Di Rosa M Pharmacol Res; 1992 Jan; 25(1):1-12. PubMed ID: 1371190 [TBL] [Abstract][Full Text] [Related]
55. Medium viscosity regulates the activity of membrane-bound and soluble phospholipase A2. Yedgar S; Reisfeld N; Halle D; Yuli I Biochemistry; 1987 Jun; 26(12):3395-401. PubMed ID: 2958081 [TBL] [Abstract][Full Text] [Related]
56. Inhibition of lysosomal phospholipase A and phospholipase C by chloroquine and 4,4'-bis(diethylaminoethoxy) alpha, beta-diethyldiphenylethane. Matsuzawa Y; Hostetler KY J Biol Chem; 1980 Jun; 255(11):5190-4. PubMed ID: 6246100 [No Abstract] [Full Text] [Related]
57. BMS-229724 is a tight-binding inhibitor of cytosolic phospholipase A2 that acts at the lipid/water interface and possesses anti-inflammatory activity in skin inflammation models. Burke JR; Davern LB; Stanley PL; Gregor KR; Banville J; Remillard R; Russell JW; Brassil PJ; Witmer MR; Johnson G; Tredup JA; Tramposch KM J Pharmacol Exp Ther; 2001 Jul; 298(1):376-85. PubMed ID: 11408565 [TBL] [Abstract][Full Text] [Related]
58. Diethylaminoethoxyhexestrol inhibition of purified rat liver lysosomal phospholipase A1: role of drug binding to substrate. Kubo M; Hostetler KY J Pharmacol Exp Ther; 1987 Jan; 240(1):88-92. PubMed ID: 3027309 [TBL] [Abstract][Full Text] [Related]
59. Effects of the anti-inflammatory serine esterase inhibitor, FOY, on phospholipase A2 (EC 3.1.1.4) activity in rabbit polymorphonuclear leukocytes. Kunze H; Bohn E; Damerau B Pharmacol Res Commun; 1983 Oct; 15(9):869-78. PubMed ID: 6417683 [TBL] [Abstract][Full Text] [Related]
60. Antiflammins. Anti-inflammatory activity and effect on human phospholipase A2. Cabré F; Moreno JJ; Carabaza A; Ortega E; Mauleón D; Carganico G Biochem Pharmacol; 1992 Aug; 44(3):519-25. PubMed ID: 1387313 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]